Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 220,239
  • Shares Outstanding, K 40,263
  • Annual Sales, $ 114,470 K
  • Annual Income, $ 22,300 K
  • 60-Month Beta 1.21
  • Price/Sales 1.93
  • Price/Cash Flow 8.50
  • Price/Book 1.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.14
  • Number of Estimates 2
  • High Estimate 0.17
  • Low Estimate 0.12
  • Prior Year 0.14
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.37 +1.86%
on 05/29/19
5.75 -4.87%
on 05/22/19
-0.26 (-4.54%)
since 05/17/19
3-Month
5.37 +1.86%
on 05/29/19
6.70 -18.36%
on 04/16/19
-0.44 (-7.45%)
since 03/18/19
52-Week
4.63 +18.14%
on 12/14/18
6.70 -18.36%
on 04/16/19
+0.34 (+6.73%)
since 06/18/18

Most Recent Stories

More News
Kamada (KMDA) Tops Q1 Earnings and Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 5.47 (-0.36%)
Kamada Reports Financial Results for First Quarter of 2019

-- Q1 2019 Proprietary Products Revenues up 67% Year-over-Year

KMDA : 5.47 (-0.36%)
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?

Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.

KMDA : 5.47 (-0.36%)
LOGC : 14.98 (+7.54%)
CTST : 4.93 (-1.40%)
TAK : 17.22 (+0.88%)
Kamada (KMDA) Stock Moves -1.05%: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.67, moving -1.05% from the previous trading session.

KMDA : 5.47 (-0.36%)
Kamada to Report First Quarter 2019 Financial Results and Host Conference Call on May 14

Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the first quarter and ended March 31, 2019, prior to the open...

KMDA : 5.47 (-0.36%)
Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed the most recent trading day at $5.83, moving +1.57% from the previous trading session.

KMDA : 5.47 (-0.36%)
Kamada (KMDA) Gains As Market Dips: What You Should Know

Kamada (KMDA) closed at $6.13 in the latest trading session, marking a +0.02% move from the prior day.

KMDA : 5.47 (-0.36%)
Is Kamada (KMDA) Stock Outpacing Its Medical Peers This Year?

Is (KMDA) Outperforming Other Medical Stocks This Year?

KMDA : 5.47 (-0.36%)
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H

Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.

PDLI : 3.00 (+0.33%)
MRUS : 13.85 (+4.45%)
KMDA : 5.47 (-0.36%)
TAK : 17.22 (+0.88%)
Kamada announces FDA acceptance of Inhaled AAT program path forward

Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food and Drug Administration (FDA or the Agency) stating that the Company...

KMDA : 5.47 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade KMDA with:

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

2nd Resistance Point 5.53
1st Resistance Point 5.50
Last Price 5.47
1st Support Level 5.43
2nd Support Level 5.38

See More

52-Week High 6.70
Fibonacci 61.8% 5.91
Fibonacci 50% 5.66
Last Price 5.47
Fibonacci 38.2% 5.42
52-Week Low 4.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar